Step by Stepa HemeOncBuddy patient portal

TCHP

Illustration: TCHP

Say it: tee-see-aitch-PEE

Docetaxel, carboplatin, trastuzumab and pertuzumab

TCHP combines two chemotherapy medicines with two HER2 targeted antibodies, and it is often given before surgery for HER2 positive breast cancer.

Also called: TCH plus pertuzumab, TCH, TCHP chemo, docetaxel carboplatin Herceptin Perjeta, TCH-Phesgo, TCHP with Phesgo

What it is

HER2 is a protein that drives some breast cancers to grow fast. Trastuzumab and pertuzumab block HER2 in two different ways, and the chemotherapy kills dividing cancer cells. Giving it before surgery can shrink the cancer and show how well it responds. The goal is cure.

TTaxotere (docetaxel)
Ccarboplatin
HHerceptin (trastuzumab)
PPerjeta (pertuzumab)

Often used for

With Phesgo (shot form)
Trastuzumab and pertuzumab can be given together as one shot under the skin of the thigh, which takes minutes instead of hours.
HER2 therapy after surgery
After surgery, trastuzumab with or without pertuzumab continues to finish about 1 year. If cancer is still found at surgery, your team may switch to a different HER2 medicine (trastuzumab emtansine).

The medicines in this plan

Docetaxel
Taxane chemotherapy. Given through a vein over about 1 hour on day 1.
Carboplatin
Platinum chemotherapy. Given through a vein over 30 to 60 minutes on day 1.
Trastuzumab
Antibody that blocks HER2. Given through a vein (or as a shot) on day 1; the first dose takes longer.
Pertuzumab
Antibody that blocks HER2 in a different spot than trastuzumab. Given through a vein on day 1.

How you get it

TCHP is given in an outpatient infusion clinic every 21 days for 6 cycles (about 4 months). The first day can take 5 to 6 hours because the first antibody doses go in slowly; later days are shorter. Many people have a port. The HER2 antibodies usually continue after chemotherapy ends to complete about 1 year. Your schedule may be different.

A typical cycle

Day before
Start dexamethasone pills to prevent reactions and fluid buildup from docetaxel.
Day 1
Blood tests, then pertuzumab, trastuzumab, docetaxel and carboplatin through a vein. You are watched after the antibodies for reactions.
Day 2
White blood cell booster shot (or on-body injector) in many cases.
Days 3 to 10
Diarrhea, tiredness and nausea are most likely. Blood counts are lowest around days 7 to 12.
Days 11 to 21
Recovery. Visit and blood tests before the next cycle.

Common side effects and what helps

Call your care team right away if you have

Good to know

At home

Questions to ask

Breast cancer

Sources

Quick answers

What is TCHP?
TCHP combines two chemotherapy medicines with two HER2 targeted antibodies, and it is often given before surgery for HER2 positive breast cancer. Docetaxel, carboplatin, trastuzumab and pertuzumab.
What does TCHP stand for?
T = Taxotere (docetaxel); C = carboplatin; H = Herceptin (trastuzumab); P = Perjeta (pertuzumab).
How is TCHP given?
TCHP is given in an outpatient infusion clinic every 21 days for 6 cycles (about 4 months). The first day can take 5 to 6 hours because the first antibody doses go in slowly; later days are shorter. Many people have a port. The HER2 antibodies usually continue after chemotherapy ends to complete about 1 year. Your schedule may be different.
What are the common side effects of TCHP?
Diarrhea, which is very common with pertuzumab. Tiredness. Low blood counts, including low platelets and anemia from carboplatin. Hair loss. Nausea and taste changes. Mouth sores. Nail changes and dry skin or rash. Tingling in fingers and toes, and swelling from fluid.
When should I call my care team during TCHP?
A fever of 100.4 degrees Fahrenheit (38 degrees Celsius) or higher, or chills; Diarrhea 4 or more times a day above normal, or diarrhea with dizziness or weakness; Shortness of breath, swelling of the legs, or a racing or pounding heartbeat; Chills, rash, wheezing or face swelling during or after the infusion; Unusual bleeding or bruising; Vomiting or you cannot keep fluids down.

Last updated: 2026-10-27. Medically reviewed by Veli Bakalov, MD, medical oncologist (October 2026). General education from Step by Step, the patient portal of HemeOncBuddy.